S. Beslija

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

Alfonso Dueñas‐González, Juan José Zarbá, Firuza D. Patel et al. · Journal of Clinical Oncology · 2011 · 468 citations · Full text

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

István Láng, Thomas Brodowicz, Larisa Ryvo et al. · The Lancet Oncology · 2013 · 85 citations

Breast Oncology, Oncology, Medicine +8

Colorectal Cancer Surgical Treatment, our Experience

Mirhan Salibasic, Sadat Pusina, Emir Bičakčić et al. · Medical Archives · 2019 · 67 citations · Full text

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

Christoph Zielinski, S. Beslija, Zrinka Mršić-Krmpotić et al. · Journal of Clinical Oncology · 2005 · 63 citations · Full text

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Christoph Zielinski, István Láng, Moshe Inbar et al. · The Lancet Oncology · 2016 · 58 citations

Breast Oncology, Oncology, Cancer Management +9